Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved

Diseases of the Colon and Rectum

Volumn 56, Issue 12, 2013, Pages 1366-1372

  Dayal, Sanjeev ^a   Taflampas, Panagiotis ^a   Riss, Stefan ^a   Chandrakumaran, Kandiah ^a   Cecil, Thomas D ^a   Mohamed, Faheez ^a   Moran, Brendan J ^a  

^a BASINGSTOKE AND NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

Author keywords

Complete cytoreduction; Maximal tumor debulking surgery; Mucinous appendiceal neoplasm; Pseudomyxoma peritonei

Indexed keywords

ADULT; AGED; APPENDIX TUMOR; ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; COMPLETE CYTOREDUCTIVE SURGERY; CYTOREDUCTIVE SURGERY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MAXIMAL TUMOR DEBULKING SURGERY; MORBIDITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERITONEUM PSEUDOMYXOMA; POSTOPERATIVE COMPLICATION; SURGICAL MORTALITY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; MALE; MIDDLE AGED; MITOMYCIN; MULTIVARIATE ANALYSIS; NEOPLASM, RESIDUAL; PERITONEAL NEOPLASMS; PSEUDOMYXOMA PERITONEI; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84888334836     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1097/DCR.0b013e3182a62b0d     Document Type: Article

References (21)

1. Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2008;34: 196-201.
2. Moran B, Baratti D, Yan TD, Kusamura S, Deraco M. Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol. 2008;98: 277-282.
3. Gough DB, Donohue JH, Schutt AJ, et al. Pseudomyxoma peritonei: long-term patient survival with an aggressive regional approach. Ann Surg. 1994;219: 112-119.
4. Mohamed F, Moran BJ. Morbidity and mortality with cytoreductive surgery and intraperitoneal chemotherapy: the importance of a learning curve. Cancer J. 2009;15: 196-199.
5. Nakakura EK. Pseudomyxoma peritonei: more questions than answers. J Clin Oncol. 2012;30: 2429-2430.
6. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221: 29-42.
7. Youssef H, Newman C, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ. Operative findings, early complications, and longterm survival in 456 patients with pseudomyxoma peritonei syndrome of appendiceal origin. Dis Colon Rectum. 2011;54: 293-299.
8. Ba MC, Cui SZ, Lin SQ, et al. Chemotherapy with laparoscopeassisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites. World J Gastroenterol. 2010;16: 1901-1907.
9. Chua TC, Liauw W, Zhao J, Morris DL. Upfront compared to delayed cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei is associated with considerably lower perioperative morbidity and recurrence rate. Ann Surg. 2011;253: 769-773.
10. Bevan KE, Mohamed F, Moran BJ. Pseudomyxoma peritonei. World J Gastrointest Oncol. 2010;2: 44-50.
11. Moran BJ. Commentary on 'Survival of patients with pseudomyxoma peritonei treated by serial debulking'. Colorectal Dis. 2010;12: 872-873.
12. Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg. 2009;249: 900-907.
13. Moran BJ. Decision-making and technical factors account for the learning curve in complex surgery. J Public Health (Oxf). 2006;28: 375-378.
14. Smeenk RM, Verwaal VJ, Zoetmulder FA. Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg. 2007;94: 1408-1414.
15. Yan TD, Links M, Fransi S, et al. Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy-a journey to becoming a Nationally Funded Peritonectomy Center. Ann Surg Oncol. 2007;14: 2270-2280.
16. Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30: 2449-2456.
17. Yan TD, Bijelic L, Sugarbaker PH. Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms. Ann Surg Oncol. 2007;14: 2289-2299.
18. Glehen O, Mohamed F, Sugarbaker PH. Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg. 2004;240: 278-285.
19. Chua TC, Baker B, Yan TD, Zhao J, Morris DL. Palliative effects of an incomplete cytoreduction combined with perioperative intraperitoneal chemotherapy. Am J Clin Oncol. 2010;33: 568-571.
20. Alves S, Mohamed F, Yadegarfar G, Youssef H, Moran BJ. Prospective longitudinal study of quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei. Eur J Surg Oncol. 2010;36: 1156-1161.
21. McQuellon RP, Loggie BW, Fleming RA, Russell GB, Lehman AB, Rambo TD. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol. 2001;27: 65-73.